Browsing: Diagnostics Techreport

Fluxergy is collaborating with Mass General Brigham (MGB) to evaluate Fluxergy’s research-use-only COVID-19 molecular-testing platform. Fluxergy will work with the MGB Center for COVID Innovation, which was launched in late March. The so-called Diagnostic Accelerator is a collaboration between the Wyss Institute and Brigham and Women’s Hospital that aims to speed up the commercialization of innovative diagnostic tests. Fluxergy’s diagnostic system comprises consumable “lab-on-chip” test cartridges called Fluxergy Cards, the Fluxergy Analyzer and FluxergyWorks software. It can provide results in under an hour, and is designed to be cost-effective and scalable, using proprietary printed circuit-board manufacturing and microfluidics technologies. See…

Read More

Transcript of discussion between NIH’s Dr. Bruce Tromberg and Dr. Frances Collins on NIH efforts to develop rapid COVID-19 test using a “RADx” a venture capitalist “shark tank” strategy to discover and fund in bold ideas with hopes of commercial tests on market by September.  In the United States, where there are approximately 400,000 to 900,000 novel COVID-19 tests per day, most testing is still being done in laboratories or complex facilities, where it takes a while for those tests to be processed and for people to get results. The National Institute of Health’s Dr. Frances Collins and Dr. Bruce Tromberg come…

Read More

As Reported in Tech Crunch. Everlywell was one of the first startups to announce that it was working on a self-administered, at-home COVID-19 diagnostic kit, but it initially sought out to ship kits before regulators made clear that this was not in line with its guidelines. Everlywell then became intent on working with the FDA to secure a proper Emergency Use Authorization for its kits before sending any to consumers, and that approach has paid off with the U.S. drug regulator issuing an EUA for Everlywell’s tech today. Everlywell‘s COVID-19 Test Home Collection Kit is the first standalone sample collection…

Read More

Sanofi and Luminostics to develop COVID-19 smartphone-based self-testing solution Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution using Luminostics’ innovative technology. a smartphone-based solution that eliminates the current need for healthcare professional administration or laboratory tests. A self-testing could help providemwhether or not they are infected” with respiratory samples in 30 minutes or less. The system involves smartphone’s optics, controlled by an iOS/Android app paired with an inexpensive adapter. It is combination with “glow-in-the-dark” nanochemistry and signal processing artificial intelligence. The diagnostic platform is composed of: an iOS/Android app to instruct a user on how…

Read More

A diagnostic test as simple to use as a pregnancy test. Researchers at the Broad Institute in Cambridge, Mass. announced in early May a prototype of a quick and inexpensive test for the coronarvirus, at around $6, they hope. This could overcome the shortcomings of the PCR Test. Dr. Feng Zhang and his colleagues posted a description of their device on the website STOPCovid dedicated to their project which. Dr. Zhang and his colleagues hope to fill that gap with tests that are affordable and easy enough to use without special expertise, according to The New York Times, which first…

Read More

E25Bio, a Cambridge, Massachusetts-based biotech startup that develops diagnostic tests for infectious diseases like dengue and Zika, has a new rapid antigen test for Covid-19. The company’s technologies grew out of an MIT lab led by Lee Gehrke, Professor at the Institute for Medical Engineering and Science (IMES), and Irene Bosch, then a research scientist at IMES. The startup recently raised $2 million from investors to specifically develop and manufacture testing kits for Covid-19. E25Bio’s rapid diagnostic test resembles an over-the-counter pregnancy test and provides visual results within 15 minutes by detecting the presence of the virus in the patient sample. As a point…

Read More